Wedbush Forecasts Arcus Biosciences' Q1 Earnings (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities researchers at Wedbush increased their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a note issued to investors on Tuesday, February 25th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($1.08) per share for the quarter, up from their previous forecast of ($1.31). Wedbush has a "Outperform" rating and a $36.00 price target on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.16) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $3.71 EPS.

Several other equities research analysts have also commented on the stock. Bank of America cut their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Morgan Stanley decreased their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Finally, HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $30.25.

Remove Ads

Arcus Biosciences Stock Performance

Shares of NYSE RCUS traded down $0.85 during midday trading on Friday, reaching $9.65. 969,467 shares of the stock were exchanged, compared to its average volume of 710,609. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a 50-day simple moving average of $13.26 and a two-hundred day simple moving average of $15.36. Arcus Biosciences has a twelve month low of $9.65 and a twelve month high of $19.69. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -3.06 and a beta of 0.84.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company's stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Institutional Investors Weigh In On Arcus Biosciences

A number of large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after purchasing an additional 833 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Arcus Biosciences by 2.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company's stock valued at $471,000 after buying an additional 843 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Arcus Biosciences by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after buying an additional 1,117 shares during the period. R Squared Ltd purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $26,000. Finally, Teacher Retirement System of Texas boosted its position in Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock worth $223,000 after acquiring an additional 2,410 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.